This trial is evaluating whether Lenalidomide will improve 2 primary outcomes, 6 secondary outcomes, and 2 other outcomes in patients with Lymphoma, Follicular. Measurement will happen over the course of 28 days.
This trial requires 33 total participants across 2 different treatment groups
This trial involves 2 different treatments. Lenalidomide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Patient and pathologic features and their inter-relations are the best predictors of the outcome of any type of non-Hodgkin's lymphoma. Lymphoma responds well to chemotherapy but not to surgery, radiotherapy, or bone marrow transplantation. Treatment modalities that are often in use, such as surgery, radiotherapy, intensive chemotherapy, and hematopoietic-cell salvage have a relatively low complete response rate. In addition, treatment failures, non-relapsing disease occurring after treatment cessation, and progression of disease from a nadir after successful treatment result in a high disease progression rate in non-Hodgkin's lymphoma.
Lymphoplvoma has multiple etiologies including genetic, immunological, and environmental factors. Risk factors associated with lymphoma may include infection, drugs, and exposure to carcinogens. The most common types of lymphoma in men and women are non-Hodgkin's lymphoma, nodular lymphoma, splenic marginal zone lymphoma, and follicular lymphoma.
Signs of lymphoma, follicular include a rapidly enlarging lymphadenopathy (including those arising in the mediastinum via the subclavian artery), a B symptom (such as fever, night sweats or weight loss), and an abnormal result from bone marrow examination. A high-grade lymphoma does not cause a B symptom. Lymphoma, follicular can be diagnosed in an individual if positive serum lymphocyte markers (e.g., elevated gamma glutamyl transpeptidase) are present, the B symptom is present, or bulky lymphadenopathy is present.
The lymphoma, follicular is a histopathologic category that is characterized by the growth of abnormal lymphocytes (i.e. germinal center cells) in follicles. The disorder can frequently be diagnosed in children and there seems to be no sex preference. Although the disease shows characteristic histopathologic features that are present in children and adults, the diagnosis depends upon whether the patient is >18 years old. The disease is rare and tends to progress rapidly. However, lymphoma, follicular is not a rare disease in children. The disease has several types and it may not always be the neoplastic type that is the focus of the diagnosis.
The incidence of lymphoma is low in the United States with an annual rate of 1.8 cases per 100,000. The incidence is higher in the elderly. While not statistically significant, the age of diagnosis for follicular and diffuse large-cell lymphomas was higher than that for all chronic lymphocytic leukemias.
Chemical chemotherapy is the most frequently used treatment for [follicular lymphoma](https://www.withpower.com/clinical-trials/follicular-lymphoma). Radiation may be used to treat stage III or IV follicular lymphoma. Radiation therapy is an effective method of treating cervical lymphoma (stage IA). Lymphoma, follicular, may be managed by surgery alone. Chemotherapy is the preferred treatment for advanced lymphoma of the stomach and intestine. Treatment for Hodgkin's disease is highly dependent on the stage of disease. Localized irradiation of Hodgkin's disease can cure the disease, but is usually restricted to the early stages of untreated disease. Radiation therapy and chemotherapy alone for patients with advanced disease is the standard of care.
Overall outcome data show very high remission rates compared to other IMDs based on both clinical trials and clinical experience. This was in particular true for bortezomib/lenalidomide. Patients with FL were more likely to achieve remissions, whereas those with mantle-cell lymphoma (MCL) were more likely to achieve complete responses. It should be kept in mind that our cohort of patients was very narrow, as all patients suffered from FL. For that reason, the overall response rate to lenalidomide in FL was relatively small, making comparison to other IMDs problematic.
Treatment of refractory or refractory relapsed lymphoma and myeloma in post-HSCT is worthwhile.Lenalidomide is an active agent with good tolerability, but there are no major differences in treatment efficacy, time to progression of disease or time to progression of disease to progression of disease when comparing different regimens. Randomised, controlled, phase III studies are warranted to assess long-term efficacy of lenalidomide-containing regimens.
Lenalidomide is used alone or in combination with other treatments. The most common treatment combinations are lenalidomide and ATG or thalidomide. Lenalidomide-based regimens have been most commonly administered in treatment-naive patients, and lenalidomide has also been used as maintenance therapy. Lenalidomide is not a commonly used treatment or prophylaxis in patients with myelodysplastic/myeloproliferative disorders.
There are many different kinds of lymphomas. The most common types of lymphoma are diffuse large B-cell lymphomas and follicular lymphomas. The two types are not the only types of lymphoma that are common. Even though it is not part of the standard of care for lymphoma to mention which type of lymphoma is the underlying disease, it is very useful to be able to pinpoint the type, as certain kinds of lymphomas that are highly responsive to treatments can be very dangerous when misdiagnosed. Lenalidomide has been shown to be very effective for most kinds of lymphomas, but it may not work the same for all cases.
There was no difference in response rates between trials with follicular lymphoma and those with non-follicular NHLs. Clinicians may consider the patient's age, baseline performance status, and disease burden in determining if clinical trial participation is appropriate.
There is ample evidence of its antitumor activity and its safety in people with lymphoma, justifying its place as the gold standard for maintenance therapy in the setting of first-line regimens and at other stages of therapy.